Tareq Abou-Khamis, MD
Rheumatology · Houston, TXNPI 1851587612
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,589 of the $116,348 with a category attached, or 67.5%. 36 manufacturers reported payments, led by Mallinckrodt Enterprises LLC at 50.4% of the total. Reporting peaked in 2019 at $84,721 and has fallen 97.5% since, to $2,096 in 2025. Among rheumatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 934 payments — averaging $124.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$59K
- Bristol Myers Squibb$20K
- Amgen$19K
- Johnson & Johnson$4K
- AstraZeneca$3K
- AbbVie$2K
- plus $10K from 30 others
What the payments were for
- Consulting fees$8,4687%
- Speaking & faculty fees$78,58968%
- Travel & lodging$11,18410%
- Food & beverage$18,05416%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 81 | $58,591 |
| Bristol Myers Squibb | 50 | $19,563 |
| Amgen(2 entities) | 135 | $19,374 |
| Johnson & Johnson | 68 | $3,623 |
| AstraZeneca(2 entities) | 52 | $2,892 |
| AbbVie | 133 | $2,343 |
| UCB, Inc. | 84 | $2,224 |
| Mallinckrodt Hospital Products Inc. | 20 | $2,071 |
| Novartis | 41 | $1,073 |
| E.r. Squibb & Sons, L.L.C. | 74 | $977 |
| Lilly USA, LLC | 49 | $874 |
| Pfizer | 41 | $598 |
| Sanofi | 20 | $442 |
| GSK | 23 | $429 |
| ANI Pharmaceuticals, Inc. | 9 | $216 |
| Aurinia Pharma U.S., Inc. | 9 | $182 |
| Genentech USA, Inc. | 5 | $91 |
| Radius Health, Inc. | 5 | $84 |
| Sobi, Inc | 4 | $77 |
| Fresenius Kabi USA, LLC | 4 | $76 |
| Boehringer Ingelheim | 3 | $72 |
| Medexus Pharma, Inc. | 5 | $69 |
| Hikma Pharmaceuticals USA | 3 | $69 |
| Tersera Therapeutics LLC | 2 | $63 |
| Actelion Pharmaceuticals US, Inc. | 3 | $48 |
| American Regent | 1 | $29 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| Gilead | 1 | $26 |
| Alvogen Inc | 1 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Sandoz | 1 | $19 |
| Celltrion USA Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,348 in reported general payments places this provider in the 90th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 56 | $400,973 |
| Cimzia (2 Pack)Certolizumab Pegol | 38 | $247,018 |
| Humira(Cf) PenAdalimumab | 27 | $188,184 |
| Humira PenAdalimumab | 21 | $186,738 |
| RinvoqUpadacitinib | 26 | $178,072 |
| Xeljanz XrTofacitinib Citrate | 31 | $176,822 |
| EnbrelEtanercept | 14 | $105,819 |
| Orencia ClickjectAbatacept | 18 | $103,041 |
| Taltz AutoinjectorIxekizumab | 12 | $81,560 |
| OtezlaApremilast | 13 | $77,022 |
| ProliaDenosumab | 13 | $21,895 |
| Leflunomide | 92 | $7,528 |
| MethotrexateMethotrexate Sodium | 211 | $3,377 |
| Hydroxychloroquine Sulfate | 116 | $2,895 |
| Prednisone | 300 | $1,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Cimzia (2 Pack) | $2,224 | $247,01838 claims |
| AmgenEnbrel, Otezla, Prolia | $19,374 | $204,73640 claims |
| AbbVieRinvoq | $2,343 | $178,07226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Houston
- Naureen AlimHouston$397K
- Shervin AssassiHouston$329K
- Maureen MayesHouston$84K
- Maria Suarez AlmazorHouston$72K
- John ReveilleHouston$61K
- Michelle EisenbergHouston$53K
- Alfredo SardinasHouston$52K
- Adnan PeerHouston$49K
- Mujahed AlikhanHouston$41K
- Dianne WollastonHouston$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.